Opening of the Radspherin® Production and Laboratory Facility
Press Release 08.2017: Oncoinvent held an opening ceremony for its new production and lab facilities today. A total of 40 guests attended the opening.
The new production facility contains a dedicated Grade B clean room, two Category B type isotope production suites, a quality control laboratory, and packaging area that will support qualified operations for manufacturing, analytical control, packaging and labelling of Radspherin® for upcoming preclinical and clinical studies.
Jan A. Alfheim, Oncoinvent’s CEO commented: “This event marks a highlight in a year that has seen tremendous growth in the company. The opening of our new laboratory and production facilities represents a significant achievement for the company and will enable the company to move Radspherin® rapidly into the next phase of development in 2018.”
Radspherin® is a novel alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities. The radium based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be treatment of peritoneal carcinomatosis originating from ovarian cancer. Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.
Oncoinvent AS is a privately held Norwegian company based in Oslo, Norway. The company is committed to developing new innovative products to provide better treatment options to cancer patients.
The company's founders started Oncoinvent in 2010 with a view to designing better cancer treatments by applying known physical and chemical principles of selected novel materials in new ways to maximize their medical benefit while minimizing potential safety concerns. This approach has allowed the company to develop a rich development pipeline and to explore multiple technological avenues before selecting a lead product candidate for preclinical testing.
For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Ole Peter Nordby, Chief Financial Officer
Cell: +47 41 28 71 79